CTIBIOTECH invests €3M and secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance
CTIBIOTECH™, an innovative French Contract Research, Development, and Manufacturing Organization (CRDMO) based in Meyzieu-Lyon, proudly announces the launch of the CTIONCOTEST ™ project, a groundbreaking €3 million initiative aimed at transforming preclinical cancer research. To accelerate this critical innovation, CTIBIOTECH ™ has been awarded €1.25 million in funding from Bpifrance under the “Aide au Développement Deeptech” program, with the strategic support of France 2030 and the Government of France.
